Tempus AI (TEM) Secures FDA Clearance for AI-Powered Heart Monitoring Software

Tempus AI, Inc. (NASDAQ:TEM) is one of the top 10 medical AI companies to buy according to analysts. On July 16, the company confirmed that it had received clearance from the US Food and Drug Administration under the 510(k) process. The clearance is for the company’s Tempus ECG-Low EF software, designed to identify patients with a low left ventricular ejection fraction.

Tempus AI (TEM) Secures FDA Clearance for AI-Powered Heart Monitoring Software

The AI-powered software is designed to measure the percentage of blood pumped out of each heartbeat. The software will be of great use for clinical diagnostics, ECG recordings collected at healthcare facilities.

“With Tempus ECG-Low EF, we’re adding another powerful tool to the hands of clinicians to help them identify patients at risk for serious cardiovascular conditions much earlier in their care journey,” said Brandon Fornwalt, Senior Vice President of Cardiology at Tempus.

It marks the second time Tempus AI has received FDA clearance for a cardiovascular product suite.

Tempus AI, Inc. (NASDAQ:TEM) is a technology company focused on precision medicine, utilizing artificial intelligence to enhance healthcare by improving disease diagnosis and treatment. It boasts a large library of clinical and genomic data to provide insights for healthcare professionals, aiming to personalize patient care and accelerate the development of new drugs.

While we acknowledge the potential of TEM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Farmland and Agriculture Stocks to Buy According to Billionaires and 10 Best Stocks to Buy Amid Gold Rally.

Disclosure: None. This article is originally published at Insider Monkey.